RXRX
Recursion Pharmaceuticals, Inc.$3.17+0.03 (+0.79%)Prev Close$3.15·MCap$1.36B·P/E—·Vol12.83M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
36
$12.51M
◆
Net Activity
Net Seller
$12.51M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Recursion Pharmaceuticals, Inc. (RXRX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 36 insider sales totaling $12.51M. The most recent insider transaction was by Khan Najat (director, officer: CEO and President), who sold $84.5K worth of shares on Jun 5, 2026. Recursion Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.36B.
RXRX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Khan Najat | director, officer: CEO and President | Sell | 23,588 | $3.58 | $84.5K | 2,175,796 |
| Jun 5, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.62 | $144.8K | 883,735 |
| Jun 4, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.68 | $110.4K | 6,169,863 |
| Jun 4, 2026 | Bumpus Namandje | director | Sell | 4,386 | $3.54 | $15.5K | 43,171 |
| May 27, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.08 | $123.2K | 883,735 |
| May 8, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.37 | $134.8K | 926,556 |
| May 7, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.52 | $105.6K | 6,199,863 |
| Apr 24, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.61 | $144.4K | 906,556 |
| Apr 8, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.10 | $93.0K | 6,229,863 |
| Apr 8, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.10 | $124.0K | 906,556 |
| Mar 25, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.25 | $130.0K | 906,556 |
| Mar 18, 2026 | Taylor Ben R | officer: Chief Financial Officer | Sell | 7,956 | $3.39 | $27.0K | 1,180,318 |
| Mar 11, 2026 | Khan Najat | director, officer: CEO and President | Sell | 28,298 | $3.35 | $94.7K | 2,262,085 |
| Feb 17, 2026 | Gibson Christopher | Director | Sell | 67,265 | $3.47 | $233.6K | 0 |
| Feb 17, 2026 | Hallett David | Chief Scientific Officer | Sell | 11,908 | $3.49 | $41.6K | 0 |
| Feb 17, 2026 | Khan Najat | CEO and President | Sell | 14,280 | $3.49 | $49.8K | 0 |
| Feb 17, 2026 | Taylor Ben R | Chief Financial Officer | Sell | 13,426 | $3.08 | $41.4K | 0 |
| Feb 6, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.20 | $924.0K | 6,429,863 |
| Feb 6, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.12 | $164.8K | 913,839 |
| Jan 22, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.47 | $178.8K | 913,839 |
| Jan 8, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.36 | $959.2K | 6,649,863 |
| Jan 7, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.25 | $170.0K | 933,839 |
| Dec 30, 2025 | Taylor Ben R | Chief Financial Officer | Sell | 21,383 | $4.18 | $89.4K | 761,550 |
| Dec 29, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 124,403 | $4.41 | $548.6K | 611,135 |
| Dec 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.50 | $180.0K | 913,839 |
| Dec 5, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.63 | $185.2K | 933,839 |
| Dec 4, 2025 | Borgeson Blake | Director | Sell | 220,000 | $4.37 | $961.4K | 6,869,863 |
| Nov 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.16 | $166.4K | 913,839 |
| Nov 6, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $5.21 | $208.4K | 974,229 |
| Oct 24, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $5.70 | $570.0K | 954,229 |
| Oct 10, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $6.04 | $604.0K | 974,229 |
| Sep 26, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.76 | $476.0K | 954,229 |
| Sep 12, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.71 | $471.0K | 974,229 |
| Aug 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.84 | $484.0K | 954,229 |
| Aug 19, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 36,599 | $5.52 | $202.2K | 668,197 |
| Aug 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 618,175 | $5.28 | $3.26M | 1,004,619-38% |
| Mar 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 138,574 | $6.04 | $837.0K | 1,117,450 |
| Mar 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.48 | $259.0K | 1,256,024 |
| Feb 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.90 | $316.0K | 1,273,156 |
| Jan 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.18 | $287.2K | 736,633 |
| Dec 6, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.14 | $285.6K | 736,633 |
| Nov 15, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.55 | $301.8K | 762,656 |
| Nov 14, 2024 | Borgeson Blake | Director | Sell | 11,447 | $7.64 | $87.5K | 7,066,113 |
| Nov 14, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $7.65 | $229.5K | 1,499,631 |
| Oct 31, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.72 | $76.9K | 7,077,560 |
| Oct 28, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $6.31 | $37.9K | 521,138 |
| Oct 17, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.67 | $76.3K | 7,089,007 |
| Oct 10, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $6.34 | $190.1K | 1,450,881 |
| Oct 4, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.12 | $244.8K | 762,656 |
| Oct 3, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.22 | $71.2K | 7,098,428 |
Showing 1–50 of 232
1 / 5
RXRX Insider Buying Activity
The following table shows recent insider purchases of Recursion Pharmaceuticals, Inc. (RXRX) stock reported via SEC Form 4 filings.
No insider buying activity found for RXRX in the last 12 months.
RXRX Insider Selling Activity
The following table shows recent insider sales of Recursion Pharmaceuticals, Inc. (RXRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Khan Najat | director, officer: CEO and President | Sell | 23,588 | $3.58 | $84.5K | 2,175,796 |
| Jun 5, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.62 | $144.8K | 883,735 |
| Jun 4, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.68 | $110.4K | 6,169,863 |
| Jun 4, 2026 | Bumpus Namandje | director | Sell | 4,386 | $3.54 | $15.5K | 43,171 |
| May 27, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.08 | $123.2K | 883,735 |
| May 8, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.37 | $134.8K | 926,556 |
| May 7, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.52 | $105.6K | 6,199,863 |
| Apr 24, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.61 | $144.4K | 906,556 |
| Apr 8, 2026 | Borgeson Blake | director | Sell | 30,000 | $3.10 | $93.0K | 6,229,863 |
| Apr 8, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.10 | $124.0K | 906,556 |
| Mar 25, 2026 | Gibson Christopher | director | Sell | 40,000 | $3.25 | $130.0K | 906,556 |
| Mar 18, 2026 | Taylor Ben R | officer: Chief Financial Officer | Sell | 7,956 | $3.39 | $27.0K | 1,180,318 |
| Mar 11, 2026 | Khan Najat | director, officer: CEO and President | Sell | 28,298 | $3.35 | $94.7K | 2,262,085 |
| Feb 17, 2026 | Gibson Christopher | Director | Sell | 67,265 | $3.47 | $233.6K | 0 |
| Feb 17, 2026 | Hallett David | Chief Scientific Officer | Sell | 11,908 | $3.49 | $41.6K | 0 |
| Feb 17, 2026 | Khan Najat | CEO and President | Sell | 14,280 | $3.49 | $49.8K | 0 |
| Feb 17, 2026 | Taylor Ben R | Chief Financial Officer | Sell | 13,426 | $3.08 | $41.4K | 0 |
| Feb 6, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.20 | $924.0K | 6,429,863 |
| Feb 6, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.12 | $164.8K | 913,839 |
| Jan 22, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.47 | $178.8K | 913,839 |
| Jan 8, 2026 | Borgeson Blake | director | Sell | 220,000 | $4.36 | $959.2K | 6,649,863 |
| Jan 7, 2026 | Gibson Christopher | director | Sell | 40,000 | $4.25 | $170.0K | 933,839 |
| Dec 30, 2025 | Taylor Ben R | Chief Financial Officer | Sell | 21,383 | $4.18 | $89.4K | 761,550 |
| Dec 29, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 124,403 | $4.41 | $548.6K | 611,135 |
| Dec 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.50 | $180.0K | 913,839 |
| Dec 5, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.63 | $185.2K | 933,839 |
| Dec 4, 2025 | Borgeson Blake | Director | Sell | 220,000 | $4.37 | $961.4K | 6,869,863 |
| Nov 19, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $4.16 | $166.4K | 913,839 |
| Nov 6, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $5.21 | $208.4K | 974,229 |
| Oct 24, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $5.70 | $570.0K | 954,229 |
| Oct 10, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $6.04 | $604.0K | 974,229 |
| Sep 26, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.76 | $476.0K | 954,229 |
| Sep 12, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.71 | $471.0K | 974,229 |
| Aug 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 100,000 | $4.84 | $484.0K | 954,229 |
| Aug 19, 2025 | Khan Najat | Chief R&D Commercial Officer | Sell | 36,599 | $5.52 | $202.2K | 668,197 |
| Aug 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 618,175 | $5.28 | $3.26M | 1,004,619-38% |
| Mar 28, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 138,574 | $6.04 | $837.0K | 1,117,450 |
| Mar 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.48 | $259.0K | 1,256,024 |
| Feb 7, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.90 | $316.0K | 1,273,156 |
| Jan 13, 2025 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.18 | $287.2K | 736,633 |
| Dec 6, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.14 | $285.6K | 736,633 |
| Nov 15, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $7.55 | $301.8K | 762,656 |
| Nov 14, 2024 | Borgeson Blake | Director | Sell | 11,447 | $7.64 | $87.5K | 7,066,113 |
| Nov 14, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $7.65 | $229.5K | 1,499,631 |
| Oct 31, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.72 | $76.9K | 7,077,560 |
| Oct 28, 2024 | Marriott Tina | President and COO | Sell | 6,000 | $6.31 | $37.9K | 521,138 |
| Oct 17, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.67 | $76.3K | 7,089,007 |
| Oct 10, 2024 | Secora Michael | Chief Financial Officer | Sell | 30,000 | $6.34 | $190.1K | 1,450,881 |
| Oct 4, 2024 | Gibson Christopher | Chief Executive Officer | Sell | 40,000 | $6.12 | $244.8K | 762,656 |
| Oct 3, 2024 | Borgeson Blake | Director | Sell | 11,447 | $6.22 | $71.2K | 7,098,428 |
RXRX Insiders
Similar Stocks to RXRX
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B